Sun Pharmaceutical Industries Limited has successfully completed the allotment of rated, listed, unsecured, redeemable, non-convertible debentures (NCDs) worth ₹7,816 crore on a private placement basis. The issuance comprised Series A NCDs valued at ₹2,003 crore and Series B NCDs at ₹5,813 crore. This private placement effectively utilized the base issue size and a portion of the greenshoe option, strengthening the company’s financial resources.
Sun Pharma Completes Private Placement of NCDs
Sun Pharmaceutical Industries Limited announced today, October 26, 2026, the successful completion of its private placement for Non-Convertible Debentures (NCDs). The total aggregate face value of the allotted NCDs amounts to INR 7,816 crore. These debentures are rated, listed, unsecured, and redeemable, and were issued on a private placement basis.
Breakdown of NCD Allotment
The total issuance is divided into two series:
- Series A NCDs: These have an aggregate face value of INR 2,003 crore.
- Series B NCDs: These comprise an aggregate face value of INR 5,813 crore.
The company initially aimed for a base issue size of INR 7,000 crore, which was fully subscribed. Based on the bids received and accepted, Sun Pharma exercised the greenshoe option, raising an additional ₹816 crore out of a potential greenshoe option of up to INR 3,000 crore. The aggregate issue consideration for the NCDs allotted is INR 7,816.02 crore.
Debenture Details
The NCDs are proposed to be listed on both the BSE Limited and the National Stock Exchange of India Limited. Series A Debentures carry an interest rate of 8.05% p.a., while Series B Debentures offer 8.20% p.a. Both series have a tenor of 5 years and 1 day from the deemed date of allotment (October 26, 2026), with a scheduled redemption date of October 27, 2031. Series A NCDs also include a put option exercisable on March 27, 2028.
Source: BSE
